Premium
Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience
Author(s) -
Desterro Joana,
McLornan Donal P.,
Curto Garcia Natalia,
O'Sullivan Jennifer,
Alimam Samah,
Keohane Clodagh,
Woodley Claire,
Francis Yvonne,
Kordasti Shahram,
Radia Deepti H.,
Harrison Claire N.
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15968
Subject(s) - medicine , tolerability , hydroxycarbamide , cohort , aspirin , referral , surgery , adverse effect , family medicine , chemotherapy
Summary Standard first‐line therapy choice for essential thrombocythaemia ( ET ) requiring cytoreduction, supported by randomized trials, is low‐dose aspirin with hydroxycarbamide, but the role of recombinant interferon‐alfa ( IFN α)‐2a/2b and pegylated ( PEG )‐ IFN ‐α‐2a/2b is increasingly highlighted. Longer‐term outcome data, however, remains somewhat scarce, particularly in the ‘real world'. We hereby report on a large, well‐annotated cohort of ET patients from a single referral centre undergoing therapy with either IFN α or ( PEG )‐ IFN ‐α‐2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long‐term therapy in a significant proportion of patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom